Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna Inc (NQ: MRNA )

44.44 +1.50 (+3.49%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Moderna Inc

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
15 16 Next >
Moderna Creates New Executive Committee Role Ahead of New Product Launches
Via ACCESSWIRE
European Medicines Agency Accepts Moderna's Conditional Marketing Authorization Filing for its Omicron BA.4/BA.5 Targeting Bivalent COVID-19 Vaccine
Via ACCESSWIRE
Novavax Remains a Risk-On Stock in a Risk-Off Market
NVAX is a risk-on stock at a time investors are turning to risk-off assets. This article looks to see if Novavax still presents an opportunity for investors 
Via MarketBeat
Topics Earnings
Exposures Financial
Indonesia's Bio Farma ready to produce IndoVac Covid-19 vaccines
Via JCN Newswire
Exposures COVID-19
Ministry Of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna's Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.214
Via ACCESSWIRE
Moderna Reviews Clinical Trial Programs Across Portfolio at 2022 R&D Day
Via ACCESSWIRE
Health Canada Authorizes Moderna's Omicron-Targeting Bivalent COVID-19 Booster Vaccine
Via ACCESSWIRE
Moderna to Host R&D Day on Thursday, September 8, 2022
Via ACCESSWIRE
Swissmedic Authorizes Moderna’s Omicron-Targeting Bivalent Booster Candidate, MRNA-1273.214
Via ACCESSWIRE
Indonesia's Bio Farma ready to produce 'IndoVac' Covid-19 vaccines
Via ACN Newswire
Exposures COVID-19
Indonesian pharmaceutical Bio Farma ready to produce IndoVac Covid-19 vaccines
Via ACN Newswire
Exposures COVID-19
Moderna to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
Via ACCESSWIRE
EMA Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion Recommending Authorization for the Use of Moderna's Omicron-Targeting Bivalent Booster in the European Union
Via ACCESSWIRE
Moderna Receives FDA Authorization for Emergency Use of Omicron-Targeting Bivalent COVID-19 Booster Vaccine for Adults 18 Years and Older
Via ACCESSWIRE
Therapeutic Goods Administration Provisionally Approves Moderna’s Omicron-Containing Bivalent Booster Candidate, MRNA-1273.214, For Australia
Via ACCESSWIRE
Moderna to Supply 12 Million Doses of Omicron-Containing Bivalent COVID-19 Booster Vaccines to the Government of Canada
Via ACCESSWIRE
Moderna Reports Second Quarter 2022 Financial Results and Provides Business Updates
Via ACCESSWIRE
Moderna Sues Pfizer and BioNTech for Infringing Patents Central to Moderna's Innovative mRNA Technology Platform
Via ACCESSWIRE
Moderna Completes Application To U.S. Food And Drug Administration For Emergency Use Authorization Of Omicron-Targeting Bivalent Covid-19 Booster Vaccine, mRNA-1273.222
Via ACCESSWIRE
James Mock Joins Moderna as Chief Financial Officer
Via ACCESSWIRE
Medicines and Healthcare Products Regulatory Agency (MHRA) Authorizes Moderna's Omicron-Containing Bivalent Booster in the UK
Via ACCESSWIRE
Two Appealing Biotech Stocks for Two Distinct investors
Investing in biotech stocks carries both risk and reward. This article highlights two biotech companies that may appeal to specific investing styles 
Via MarketBeat
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Global Multiple Sclerosis Drugs Market Size Projected To Reach $33 Billion By 2029
Palm Beach, FL –– August 11, 2022 – FinancialNewsMedia.com News Commentary – Multiple Sclerosis (MS) is an immune-mediated disease affecting the central nervous system. It is characterized by... 
Via FinancialNewsMedia
Exposures COVID-19
Moderna And the European Commission (EC) Amend Covid-19 Vaccine Agreement to Supply Omicron-Containing Bivalent Candidates; EC Purchases Additional 15 million Doses
Via ACCESSWIRE
3 Health Care Stocks in Great Financial Health
Health care’s potential to do better in both up and down markets makes it a valuable part of a long-term investment strategy. 
Via MarketBeat
Moderna Announces New Supply Contract With The U.S. Government For An Initial 66 Million Doses Of A Moderna Bivalent Covid-19 Booster Vaccine With Options For U.S. Government To Purchase Up To An Additional 234 Million Doses
Via ACCESSWIRE
Moderna Announces New Supply Contract With The U.S. Government For An Initial 66 Million Doses Of A Moderna Bivalent Covid-19 Booster Vaccine With Options For U.S. Government To Purchase Up To An Additional 234 Million Doses
New U.S. government contract includes an award up to $1.74 billion for 66 million doses to be delivered in 2022; additional options, if exercised, may raise total to 300 million doses 
From Moderna, Inc.
Via AccessWire
Exposures COVID-19 Product Safety
Is Moderna's Cheaper Valuation A Buying Signal?
Moderna is one of the least expensive companies in the S&P 500 in terms of valuation. In this article, we'll examine other aspects of the company. 
Via MarketBeat
Topics Stocks
Exposures US Equities
EMA Committee for Medicinal Products for Human Use (CHMP) Recommends Use of the Moderna COVID-19 Booster in Adolescents (12-17 Years) in the European Union
Via ACCESSWIRE
EMA Committee for Medicinal Products for Human Use (CHMP) Recommends Use of the Moderna COVID-19 Booster in Adolescents (12-17 Years) in the European Union
CAMBRIDGE, MA / ACCESSWIRE / July 22, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Medicines... 
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
15 16 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.